Title:
がん治療のための予測的バイオマーカー
Document Type and Number:
Japanese Patent JP6441320
Kind Code:
B2
Abstract:
The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.
More Like This:
Inventors:
Shrov, Matthias
Schmidt, Manuel
Cup, curstin
Witig, Burghard
Schmidt, Manuel
Cup, curstin
Witig, Burghard
Application Number:
JP2016515715A
Publication Date:
December 19, 2018
Filing Date:
May 15, 2014
Export Citation:
Assignee:
Morogen Age
International Classes:
G01N33/50; A61K31/7115; A61K39/00; A61K45/00; A61K47/50; A61P35/00; A61P37/04; A61P43/00; C12Q1/04
Domestic Patent References:
| JP2011519847A |
Foreign References:
| WO2005000348A2 | ||||
| WO2012085291A1 |
Other References:
RIERA-KNORRENSCHILD,MAINTENANCE WITH THE TLR-9 AGONIST MGN1703 VERSUS PLACEBO IN PATIENTS WITH ADVANCED COLORECTAL CARCINCOMA (MCRC): A RANDOMIZED PHASE II TRIAL (IMPACT) [ABSTRACT 3643],JOURNAL OF CLINICAL ONCOLOGY [ONLINE],2013年 5月20日,VOL:31, NR:15_SUPPL,URL,http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3643
SCHMIDT M、外11名,87 FIRST RESULTS OF A PHASE 2-3 CLINICAL STUDY WITH THE IMMUNOMODULATOR MGN1703 IN PATIENTS WITH ADVANCED COLORECTAL CARCINOMA(IMPACT STUDY),MOLECULAR THERAPY,2011年 5月,Vol.19 Supplement1,Page.S35
VARGHESE,A NOVEL INKT-MEDIATED VACCINE MANEUVER OVERCOMES PD-1-MEDIATED T CELL EXHAUSTION IN CANCER,THE JOURNAL OF IMMUNOLOGY,2012年 1月 1日,URL,http://www.jimmunol.org/cgi/content/meeting_abstract/188/1_MeetingAbstracts/165.13
SCHMIDT M、外11名,87 FIRST RESULTS OF A PHASE 2-3 CLINICAL STUDY WITH THE IMMUNOMODULATOR MGN1703 IN PATIENTS WITH ADVANCED COLORECTAL CARCINOMA(IMPACT STUDY),MOLECULAR THERAPY,2011年 5月,Vol.19 Supplement1,Page.S35
VARGHESE,A NOVEL INKT-MEDIATED VACCINE MANEUVER OVERCOMES PD-1-MEDIATED T CELL EXHAUSTION IN CANCER,THE JOURNAL OF IMMUNOLOGY,2012年 1月 1日,URL,http://www.jimmunol.org/cgi/content/meeting_abstract/188/1_MeetingAbstracts/165.13
Attorney, Agent or Firm:
Masatake Ide